All In Biotech

Drug Trial Radar · NCT03819465

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

175

Actual

Start

Dec 27, 2018

Primary completion

May 23, 2023

Study completion Jul 1, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Conditions

  • Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • DurvalumabDrug

    Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

  • DanvatirsenDrug

    Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8

  • OleclumabDrug

    Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

  • MEDI5752Drug

    MEDI5752 IV Every 3 weeks (q3w)

  • PemetrexedDrug

    Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

  • CarboplatinDrug

    Carboplatin IV Day 1 of each 21-day cycle

  • GemcitabineDrug

    Gemcitabine IV Days 1 and 8 of each 21-day cycle

  • CisplatinDrug

    Cisplatin IV Day 1 of each 21-day cycle

  • Nab-paclitaxelDrug

    Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle

  • AZD2936Drug

    AZD2936 IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of AEs by CTCAE v5.0Time frame: From informed consent until the safety follow-up visit 3 months after the last dose of study drug, or until the final data cut-off (DCO) date, whichever is earlier.

Locations

41 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Iowa City, Iowa

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Edegem, Belgium

  • Research Site

    Bialystok, Poland

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Gdansk, Poland

  • Research Site

    Grudziądz, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Tomaszów Mazowiecki, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Cheongju-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan, Taiwan

  • Research Site

    Bangkok, Thailand

  • Research Site

    Bangkok, Thailand

  • Research Site

    Chiang Mai, Thailand

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.